Active Biotech AB

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:58 2024-05-03 am EDT			5-day change	1st Jan Change
0.54 ^SEK	-1.46%		-4.76%	+18.29%

Apr. 03	Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	CI
Feb. 08	Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Annual Report 2023 Active Biotech AB (publ)

April 22, 2024 at 05:00 am EDT

Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2023 now is available for download at www.activebiotech.com.

The Annual Report will only be digitally distributed.

"I am very pleased with the progress of our projects in 2023. We are strengthened in our belief that our projects have the potential to treat diseases with great medical need. For 2024, our main goal is to start two clinical proof-of-concept studies with tasquinimod in myelofibrosis," says Active Biotech CEO Helén Tuvesson.

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

Latest news about Active Biotech AB

Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	Apr. 03	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	Dec. 22	CI
Active Biotech Raises SEK44 Million via Rights Offering	Dec. 06	MT
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	Dec. 06	MT
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	Dec. 01	CI
Active Biotech Plans SEK51 Million Rights Issue; Shares Sink	Nov. 09	MT
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	Nov. 02	CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	23-09-11	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	23-07-31	MT
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	23-07-31	CI
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	23-05-26	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Active Biotech AB Auditor Raises 'Going Concern' Doubt	23-04-25	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
Active Biotech AB Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops	23-01-30	CI
Active Biotech's Announces Nomination Committee	22-12-05	CI
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Active Biotech AB Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage	22-06-01	CI
Active Biotech AB announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis	22-05-18	CI

Chart Active Biotech AB

Duration

Period

More charts

Company Profile

Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTIVE BIOTECH AB	+18.29%	18.18M
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs